Please login to the form below

Not currently logged in
Email:
Password:

Cephalon rejects Valeant bid

Cephalon's board of directors has formally rejected Valeant Pharmaceuticals' unsolicited bid to acquire the biotech company for $5.7bn or $73 per share

Cephalon's board of directors has formally rejected Valeant Pharmaceuticals' unsolicited bid to acquire the biotech company for $5.7bn or $73 per share, a 29 per cent premium on the company's 30-day trading average.

"The Cephalon Board believes that your proposed price significantly undervalues Cephalon, its key assets and its prospects," Cephalon CEO Kevin Buchi said in an open letter to Valeant CEO J Michael Pearson.

"From the standpoint of the Cephalon shareholder, a transaction with Valeant at this time and at the price you proposed would mean foregoing the greater value obtainable from Cephalon's strategic plan, including the value inherent in our diversified and robust portfolio of marketed and pipeline products."

The board said that Valeant's bid, which was made public last week, used a "worst-case scenario" to determine Cephalon's value and that the valuation neglects the 10 late-stage products in Cephalon's pipeline. The pipeline includes six drug candidates that the company believes have blockbuster potential and that it expects it will begin to launch within the next three years.

Meanwhile, Valeant said it would begin a push to install its own directors to Cephalon's board, nominating former Quintiles president Santo J Costa, former CalPERS interim CEO Richard H Koppes, former Coventry Health Care CEO Lawrence N Kugelman, Media AB Group president and CEO Anders Lonner, former Harvard business school dean John H McArthur, and former Duke University business school dean Blair H Sheppard.

"We stand ready to quickly commence and close our transaction as proposed, unless Cephalon stockholders do not support our offer, in which case we will focus our attention on other opportunities to invest our capital," Pearson said in a statement.

6th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics